ALMIRALL S.A. EO -,12/ ES0157097017 /
10/05/2024 08:08:02 | Chg. +0.1000 | Volume | Bid21:54:31 | Ask21:54:31 | High | Low |
---|---|---|---|---|---|---|
8.9400EUR | +1.13% | 0 Turnover: 0.0000 |
-Bid Size: - | -Ask Size: - | 8.9400 | 8.9400 |
GlobeNewswire
13/03
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermat...
GlobeNewswire
05/03
Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of...
GlobeNewswire
14/11/2023
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
GlobeNewswire
14/11/2023
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for de...
GlobeNewswire
21/09/2023
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
GlobeNewswire
18/09/2023
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and No...
GlobeNewswire
12/09/2023
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockh...
GlobeNewswire
07/09/2023
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR...
GlobeNewswire
25/03/2022
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corpo...
GlobeNewswire
16/03/2022
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
GlobeNewswire
15/03/2022
ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer
GlobeNewswire
08/03/2022
Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NU...
GlobeNewswire
02/03/2022
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, ...
GlobeNewswire
16/12/2021
China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment o...
GlobeNewswire
10/11/2021
Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
GlobeNewswire
08/11/2021
Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021